Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.05 (8.333%)
Open: 0.625
High: 0.625
Low: 0.625
Prev. Close: 0.625
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Micro Focus Rises On Outlook And Buyback

Mon, 05th Nov 2018 10:57

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------Micro Focus International, up 3.0%. The software company said its annual revenue outlook is expected to come in at the better end of its previously guided range. On a constant currency basis, the company expects revenue to come in at the upper end of the guidance of a 6% to 9% decline for the financial year to October-end. Micro Focus highlighted that it traded in line with the board's expectations, as it saw revenue improvements in the second half. The company also announced its intention to recommence its share buyback programme, with any shares bought back to be held in treasury. From August 29 to October 24, Micro Focus bought back 9.9 million shares for USD171 million. The extended share buyback programme, when initiated, will cover an additional tranche of shares for up to USD400 million, inclusive of those already repurchased. ----------FTSE 100 - LOSERS----------Ashtead Group, down 3.0% at 1,905.00 pence. Barclays cut its price target on the equipment rental firm to 2,200p from 2,580p. ----------FTSE 250 - WINNERS----------Sirius Minerals, up 2.5%. The polyhalite mining company said it has awarded a contract to construct port handling facility for the Woodsmith polyhalite fertilizer mine located in north Yorkshire, England. The company's unit York Potash Processing and Ports has awarded a engineering, procurement and construction contract to civil engineering contractor McLaughlin & Harvey for developing port handling facility at Teesside, north east England. Under the contract, McLaughlin & Harvey will design and build the port storage facilities for 250,000 tonnes of product, ship loading equipment, ship outload infrastructure, and the final product screening facility. The port handling facility will store the company's polyhalite fertilizer after it has been transported from the Woodsmith mine and processed into the finished product at the Wilton Materials handling facility. ----------RPC Group, up 1.9%. The plastic product producer said it extended the deadline for talks over a potential takeover by private equity firms Apollo Global Management and Bain Capital to early December. In September, RPC confirmed that Apollo and Bain had approached it with a potential deal to buy the firm. The original deadline for Apollo and Bain to either announce a firm intention to make an offer or step away from a deal under UK takeover rules was October 8. Early in October, this was extended until 1700 GMT on Monday. RPC emphasised on Monday that "discussions remain ongoing" and consequently have agreed to extend the deadline further. With the fresh extension, the new deadline will be December 3 at 1700 GMT. The firm will provide a further announcement "when appropriate" and added there was "no certainty" an offer would be made. ----------FTSE 250 - LOSERS----------Hiscox, down 7.5%. The insurer said it enjoyed strong growth in the third quarter which saw total gross written premiums increase, but noted premium growth would slow towards the end of the year. For the nine months ended September, Hiscox reported a 14% year-on-year increase in total gross written premiums to USD3.04 billion from USD2.66 billion. Hiscox said a "benign" first half was followed by an "active" third quarter for both natural catastrophe and large claims, which has extended into October. In addition, the company said it expects growth to "moderate" over the remainder of 2018. Peel Hunt said Hiscox was unable to escape an "active" period of losses for the insurance industry, in part due to the growth of its portfolio over the past few years. In addition, Shore Capital said: "The challenging claims environment in the third quarter and muted guidance on growth for the rest of the year, however, are not positive, in our view."----------Babcock International, down 5.1%. RBC Capital downgraded the defence outsourcer to Sector Perform from Outperform. ----------OTHER MAIN MARKET AND AIM - WINNERS----------N4 Pharma, up 30%. The pharmaceutical company said MedImmune, a subsidiary of blue chip drugmaker AstraZeneca, confirmed its commitment to investigating non-lipid nanoparticle technologies for mRNA and pDNA delivery. MedImmune said it intends to continue to work with N4 Pharma to co-develop an optimised version of Nuvec under an appropriate collaboration agreement. The company's Nuvec system is intended to effectively deliver nucleic acids into cells leading to the production of antigens with potential activity as therapeutic entities or antigens for cancer vaccine. N4 Pharma partnered with MedImmune in February, following the conclusion of the Innovate UK feasibility grant. The grant was awarded to a collaborative project to explore the manufacture of a prototype nanomedicine using N4 Pharma's Nuvec system. ----------Symphony Environmental Technologies, up 10%. The 'smart' plastic maker said a report commissioned by the company by former deputy judge of the High Court in England Peter Susman said the case for oxo-biodegradable technology is "clear and compelling". Susman considered evidence from the EU Commission report from January 2018, the Loughborough Report for the UK government and the 2016 Eunomia Report. In his written opinion, Susman said oxo-biodegradable technology "does facilitate" the biodegradation of plastics in air or seawater by bacteria, fungi or algae. He believes this will "cause the plastic to cease to exist far sooner than ordinary plastics, without causing any toxicity". Susman also said the technology is compatible with composting and recycling. Chief Executive Michael Laurier said: "We are delighted that Peter Susman has found the scientific case for Symphony's d2w oxo-biodegradable technology to be proven."----------OTHER MAIN MARKET AND AIM - LOSERS----------Angus Energy, down 14% at 11.3p. The oil & gas production company said it intends to raise GBP2.0 million through a share placing for general working capital purposes and business development opportunities. Angus Energy plans to issue 22.2 million shares at a price of 9.0 pence each. The placing price represents a 23% discount to the 30-day volume weighted average share price. Angus Energy intends to use the proceeds to provide funds for general working capital purposes, principally in relation to the strategy at Brockham oil field located in Surrey, England. It also expects to use the funds to expand its portfolio of onshore development and appraisal projects.----------
More News
9 Jul 2018 08:40

N4 Pharma Shares Fall As Sildenafil Trial Falls Short Of Expectations

LONDON (Alliance News) - Shares in N4 Pharma PLC plunged early Monday as the company said that its sildenafil reformulation clinical trial has not met its key target endpoints.Shares in the

Read more
18 Jun 2018 11:54

N4 Pharma Says Team Making Progress In Nuvec Manufacturing Process

LONDON (Alliance News) - Drug reformulator N4 Pharma PLC said Monday work to develop a manufacturing process for Nuvec has begun "well" with the team making progress.Nuvec is a to

Read more
9 May 2018 14:13

N4 Pharma Files Patent For Drug To Treat Premature Ejaculation

LONDON (Alliance News) - Pharmaceutical company N4 Pharma PLC announced on Wednesday it has filed a patent application for a treatment for premature ejaculation.N4 Pharm's drug is an of

Read more
25 Apr 2018 11:54

N4 Pharma Outlook Optimistic But Loss Widens After Reverse Takeover

LONDON (Alliance News) - N4 Pharma PLC on Wednesday said it remains optimistic for future as progresses its drug and vaccine development, but the company's loss widened in 2017 following its a

Read more
18 Apr 2018 12:15

N4 Pharma Starts Clinical Trial Of Reformulated Sildenafil

LONDON (Alliance News) - N4 Pharma PLC said Wednesday that it has commenced proof of concept clinical trial for erectile dysfunction treatment drug sildenafil, following the completion of the of a

Read more
9 Mar 2018 10:43

N4 Pharma Raises Nets GBP159,700 From Warrant Exercise (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC said Friday it issued 1.9 million shares due to exercise of warrants, raising GBP159,700 for the pharmaceutical warrants

Read more
8 Mar 2018 13:34

N4 Pharma Unveils Two-Pronged Strategy For Nuvec Development

LONDON (Alliance News) - N4 Pharma PLC announced Thursday a two-fold development strategy for its Nuvec technology, as well as a new head of development for Nuvec.Nuvec

Read more
7 Mar 2018 12:41

N4 Pharma Raises Further GBP30,451 After Warrant Exercise (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC said Wednesday it issued 358,245 shares due to exercise of warrants, raising GBP30,451 for the pharmaceutical warrants at

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.